Hereditary hemorrhagic telangiectasia (HHT) is an inherited disorder in the blood vessels that can lead to a range of complications, including bleeding disorders and abnormal vascular structures in various organs. It affects about one in 5,000 people. Currently, treatment options for HHT are limited and don’t address the cause of the disease.
A new study led by MGM graduate student Evon DeBose-Scarlett (Marchuk lab) points the way toward strategies for developing more targeted and effective treatments for patients suffering from HHT, which can cause serious, even life-threatening, bleeding.
DeBose-Scarlett is the lead author on a study published in the American Journal of Human Genetics that sheds light on the genetic causes behind the vascular malfornations that are seen in HHT.
Click here to read more.